8-K: Allurion Technologies Reports Fourth Quarter and Full-Year 2024 Financial Results, Provides Business Update

Allurion Technologies announces its Q4 and full-year 2024 financial results, highlighting revenue, expense reductions, and progress in clinical trials and market access.

Summary

• Allurion Technologies reported Q4 2024 revenue of $5.6 million and full-year revenue of $32.1 million, aligning with preannouncements.
• The company's Q4 operating expenses decreased by 39% year-over-year to $19.6 million, including $3.8 million in restructuring charges.
• Procedure volume grew by 4% in 2024, exceeding previous guidance.
• Allurion has been cleared to resume sales in France as of February 12, 2025.
• Positive topline results were achieved in the AUDACITY FDA clinical trial, paving the way for a pre-market approval (PMA) application.
• Recent financing activities are expected to sustain the business through potential FDA approval of the Allurion Balloon in 2026.
• The company is advancing its R&D pipeline with a next-generation Allurion Balloon featuring a smaller capsule and increased radiopacity.
• Allurion projects approximately $30 million in revenue for 2025, with a 50% reduction in operating expenses compared to 2024.

Sentiment

Score: 6

Explanation: The sentiment is mixed; while there are positive developments like the AUDACITY trial results and expense reductions, revenue decline and cash burn raise concerns.

Positives

• Procedure volume growth of 4% exceeded previous guidance.
• Clearance to resume sales in France provides a boost to revenue potential.
• Positive topline readout from the AUDACITY trial is a significant step towards FDA approval.
• Restructuring initiatives have led to a substantial reduction in operating expenses.
• Recent financings provide a cash runway through potential FDA approval and EBITDA positivity.

Negatives

• Q4 2024 revenue decreased to $5.6 million from $8.2 million in the same period in 2023.
• Gross profit for Q4 2024 was $2.5 million, or 45% of revenue, compared to $6.4 million, or 78% of revenue, for the same period in 2023.
• The year-over-year decrease in revenue was primarily due to the temporary suspension of sales in France and macroeconomic headwinds in certain markets leading to lower re-order rates.
• Cash balance on December 31, 2024 was $15.4 million, down from $38.037 million at the end of 2023.

Risks

• The company's future performance is subject to general economic, political, and business conditions.
• Allurion's ability to obtain and maintain regulatory approval for the Allurion Program is crucial.
• The timing and results of clinical studies and trials, including those involving GLP-1 combinations, are uncertain.
• The evolution of the markets in which Allurion competes, including the impact of GLP-1 drugs, could affect demand.
• The company's ability to maintain its listing on the New York Stock Exchange is a risk factor.
• Geopolitical events like the Russia-Ukraine war and the Israel-Hamas war could impact Allurion's business and financial results.

Future Outlook

Allurion anticipates approximately $30 million in revenue for 2025 and expects to reduce operating expenses by approximately 50% compared to 2024; the company believes it has a cash runway through becoming EBITDA positive and receiving FDA approval of the Allurion Balloon.

Management Comments

• In 2024, we restructured and refocused Allurion for the future and have been thrilled with the recent milestones we have achieved, said Dr. Shantanu Gaur, Founder and Chief Executive Officer.
• Momentum built in the fourth quarter as our new commercial strategy began to take hold, and procedure volume grew most in regions where GLP-1s are relatively mature in the market, suggesting, we believe, that patients are entering the funnel seeking either an alternative or combination approach to weight loss.
• With our recent financings complete, we believe we have a cash runway through becoming EBITDA positive and receiving FDA approval of the Allurion Balloon.

Industry Context

Allurion is operating in a competitive weight loss market, facing challenges and opportunities related to the increasing popularity of GLP-1 drugs; the company is exploring combination therapies and alternative approaches to differentiate itself.

Comparison to Industry Standards

• It's difficult to directly compare Allurion's results to industry standards without knowing the specific metrics of its direct competitors in the intragastric balloon market.
• However, companies like Apollo Endosurgery (now part of Boston Scientific) and ReShape Lifesciences are key players in the bariatric surgery and non-surgical weight loss solutions space.
• Allurion's focus on a procedure-less, swallowable balloon differentiates it, but its financial performance needs to be assessed against the growth rates and profitability of these broader competitors and the impact of GLP-1 drugs on the overall market.

Stakeholder Impact

• Shareholders will be impacted by the financial performance and the company's ability to achieve FDA approval and profitability.
• Employees may be affected by restructuring initiatives and changes in operational focus.
• Customers (patients) will benefit from advancements in the Allurion Program and potential combination therapies.
• Healthcare providers will have access to the Allurion Virtual Care Suite for managing weight loss therapies.

Next Steps

• Submission of PMA application to the FDA following positive AUDACITY trial results.
• Initiation of prospective studies on the combination of the Allurion Program with low-dose GLP-1s.
• Advancement of the R&D pipeline with the launch of the next-generation Allurion Balloon.
• Focus on achieving profitability and EBITDA positivity.
• Implementation of the new commercial strategy to drive procedure volume growth.

Key Dates

Keywords

Allurion, financial results, weight loss, gastric balloon, FDA approval, revenue, operating expenses, clinical trial, AUDACITY, GLP-1, procedure volume, restructuring